ReViral
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | - | - | - | - | 12.0m | 7.3m |
| % growth | - | - | - | - | - | - | (39 %) |
| EBITDA | (3.2m) | (10.5m) | (10.1m) | (21.6m) | (24.0m) | (14.9m) | (39.1m) |
| % EBITDA margin | (425 %) | - | - | - | - | (124 %) | (535 %) |
| Profit | (1.4m) | (3.4m) | (7.5m) | (17.9m) | (21.3m) | (10.4m) | 315m |
| % profit margin | (179 %) | - | - | - | - | (87 %) | 4303 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $1.0m | Early VC | |
$21.0m | Series A | ||
* | $55.0m | Series B | |
$44.0m Valuation: $275m -11.6x EV/LTM EBITDA | Series C | ||
* | $525m Valuation: $525m 39.7x EV/LTM Revenues -32.0x EV/LTM EBITDA | Acquisition | |
| Total Funding | AUD187m | ||
Related Content
Recent News about ReViral
EditReViral is a biotechnology company focused on developing transformative antiviral therapies, particularly for Respiratory Syncytial Virus (RSV). The company serves healthcare providers and patients, especially those in high-risk populations. Operating in the pharmaceutical and biotech markets, ReViral employs a research-driven business model to create innovative treatments. Revenue is generated through the development and commercialization of antiviral drugs, supported by significant funding rounds and regulatory milestones such as FDA Fast Track Designation.
Keywords: antiviral, RSV, biotechnology, healthcare, high-risk populations, pharmaceutical, research-driven, FDA, commercialization, innovative treatments.